Explore tweets tagged as #PI3K
🧩 PTCL Summary 💊 Chemo backbone: CHOP/CHOEP → escalate only if biology supports 🧬 Stratify early: CD30, TFH phenotype, JAK/STAT, PI3K activity ➡️ Add-ons: CD30⁺ → BV-CHP ± auto-SCT TFH → Epigenetic (HMA/EZH) + CHOP STAT-high → JAK inhibitor + CHOP (trial) #SOHOKSA
0
0
0
future treatment of this patient population relies on combinations of novel SERDs/SERMs with other targeted agents, particularly those inhibiting the PI3K/AKT/mTOR signaling pathway, to successfully bypass the conventional 6-month PFS threshold. @OncoAlert #ESMO25
2
9
23
Long awaited BURAN in #ESMO2025 : A phase III study of buparlisib plus paclitaxel in patients with CPI pretreated recurrent/metastatic head and neck cancer, no OS benefit overall and in subgroups . Likely effect of post IO era . no biomarker selection for PI3K #MedIQESMO25 #HNSCC
0
1
7
Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer @NEJM
https://t.co/vHhF5XoUZE 👉Low-dose aspirin resulted in a significantly lower risk of recurrence w/ hotspot mutations 👉similar benefit w/ other alterations in PI3K pathway 🧐I would take it... @myESMO
8
77
200
NEW Breast Cancer Breakthroughs today! Learn about how new research is ushering in the next generation of PI3K inhibitors to treat breast cancer. Watch and read here: https://t.co/VDleN3u5Oa
0
0
2
In PTEN-deficient de novo mHSPC, CAPItello-281 shows: 🔹 rPFS HR 0.81 (P=0.034) for capi + abi vs abi 🔹 Trend toward improved OS 🔹 Increasing benefit at ≥95–100% PTEN loss A step forward in PI3K/AKT-targeted therapy for prostate cancer. #ProstateCancer #ESMO25
0
1
7
VIKTORIA-1 ◽study evaluating Gedatosib, a PAM inhibitor of the PI3K-AKT-mTOR pathway, in association with FULV +- Palbociclib ◽Positive study with PFS gain in this PIK3CAwt cohort, will we still need to test? @OncoAlert #ESMO25 @myESMO
1
6
11
BURAN Phase III trial #ESMO25 Buparlisib (pan-PI3K inhibitor) fails improving OS in combination with paclitaxel vs paclitaxel alone Adlai Nortye has abandoned its development in oncology @OncoAlert @brunolarvol @OncBrothers
0
6
10
New study finds that a salivary peptide from mosquitoes — sialokinin — binds human neurokinin receptors and dampens monocyte activation, reducing inflammation during Chikungunya virus infection. 🔬 Interestingly: • Sialokinin triggers PI3K/Akt signalling via NK₁R/NK₂R in
0
4
13
Join us today at 4 p.m. Eastern for the first webinar in our FREE series on current concepts in molecular testing for HR+/HER- breast cancer. Today’s session will focus on PI3K pathway and ESR1 mutations in ER+ HER2- breast cancer. Register here: https://t.co/ohIhyUgW39
0
3
4
A new clinical trial found that low-dose aspirin cut colon cancer recurrence by more than half in certain patients. Those patients with colon or rectal cancer having a PI3K pathway mutation, who were given low-dose aspirin (160 mg daily) after surgery cut the risk of recurrence
8
36
208
The evERA trial produced interesting results. The fact that the ITT analysis demonstrated an extension of PFS is significant. However, the lack of PI3K inhibitor treatment and the lack of AKT inhibitor treatment differ from the current standard of care. @OncoAlert #ESMO25
1
5
8
$CELC ... Celcuity Inc. announced detailed efficacy and safety results from the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in adults with hormone receptor positive (HR+), HER2-negative, PIK3CA wild-type advanced
2
0
14
🚨#ESMO25 update: In mHSPC w/ PTEN deficiency, targeting the PI3K/AKT pathway shows promise! 🧬 CAPItello-281: capivasertib + abiraterone improved rPFS ⏱️33.2 vs 25.7 mo (HR 0.81, p = 0.034). Greater effect w/ higher PTEN loss cutoffs. 💊 AE profile as expected for AKT
2
7
17
The next phase of our MENTAL HEALTH project is here & WE NEED YOUR HELP PLEASE: Could you spare a little time to fill out our survey: https://t.co/nvEJuwnEZ2 Thank you so much for your help Mandy & the GoPI3Ks team. @CAR_UWE those tagged could u pls can you share, thanks ☺️
0
4
2
Three pioneering longevity tokens will be introduced on @pumpdotscience soon, which focus on: Chemical partial reprogramming + Rapamycin (mTOR inhibition) + Omipalisib (dual PI3K/mTOR inhibition) By Rapamycin Longevity Lab + Reprogramming Lab Event Link:
On November 10 we will co‑host an online event that kicks off launching week on @pumpdotscience. Rapamycin Longevity, in partnership with Reprogramming Lab, will introduce three pioneering tokens on Pump Science throughout that week. We begin the event with a live launch of a
1
2
10
$KURA (L) $200M EV, running nicely ahead of ESMO KRAS, PI3K & TKIs/ $EXEL's cabo are large markets to play in as combination partner of choice Hypothesis= FTI blocks TORC1 (central mechanism for resistance across all 3) Derisking/downside cushion = zifto + Kyowa partnership
12
1
17
低用量アスピリン（160mg/日×3年）でPI3K変異を持つ局所大腸がんの再発を半減 対象：Stage I–III直腸がん／Stage II–III結腸がん＋PI3K経路変異あり ・再発率：7.7%（アスピリン）vs 14.1%（プラセボ） ・3年DFS（病気なし生存率）：アスピリン群で改善傾向 ますます個別化医療に期待です
2
3
33